InnovationRx is your go-to source for the latest healthcare news. If you want to stay updated, make sure to subscribe to our newsletter here. Melinda French Gates, the founder of Pivotal Ventures, is on a mission to empower women and increase their influence through various means such as philanthropy, advocacy, and investments. In 2023, venture capital funding for women co-founded companies reached a record high of 20%, although startups solely founded by women were only at 2%. Erin Harkless Moore, the managing director of Pivotal Ventures, believes that by providing more capital to women, they can unlock solutions to some of the most pressing societal challenges.
Harkless Moore is particularly focused on the “Care Economy,” which encompasses caregiving responsibilities amounting to approximately $648 billion. This includes tasks such as taking care of one’s health, children, and aging family members. Pivotal Ventures is actively investing in companies and women-led venture capital funds that aim to alleviate the burdens of care, reduce costs, and improve access to care.
Caregiving is a bipartisan issue, with surveys indicating that two out of three individuals believe the government should do more to address the challenges and financial implications of caregiving. Pivotal Ventures has made investments in companies like Tia, Mon Ami, and Summer Health, which offer various healthcare services for women, aging populations, and pediatric care. Additionally, the fund has invested in venture capital firms like Magnify Ventures and Define Ventures.
In the realm of drug discovery, GLP-1 drugs like Ozempic and Wegovy are not just effective for weight loss and diabetes treatment. Emerging evidence suggests that these medications could be beneficial for treating other conditions such as cancer, Alzheimer’s, and even COVID-19.
On the pipeline and deal front, eGenesis secured a substantial $191 million in a series D financing round for its genetically modified pig organs for human transplant initiative. ArsenalBio closed a $325 million series C financing round for its cell therapy programs targeting cancer. Vesta Healthcare raised $65 million to expand its virtual home-based care services. Novartis commenced the construction of two new manufacturing facilities in the U.S. for radioligand therapies to combat cancer. PatientPartner, a startup focusing on patient engagement, raised $7 million in a seed round. Haya Therapeutics entered into a research agreement with Lilly to develop genomic treatments for obesity and related conditions, potentially worth up to $1 billion in milestone payments.
Xtalpi, an AI drug discovery company based in Shenzhen, China, experienced a significant increase in its share value, driven by its revenue growth and partnerships with major companies like Pfizer and Johnson & Johnson. The company also secured a $135 million deal with GCL Group to collaborate on new material research, including lithium-ion batteries.
In other healthcare news, Rite Aid appointed an insider as its CEO as the company emerges from bankruptcy. The FDA approved an updated Novavax COVID vaccine shortly after authorizing Moderna and Pfizer’s shots. Highmark Blue Cross reported a $417 million profit as its health plans and provider network expanded. Moderna’s mRNA MPOX vaccine outperformed licensed rival shots in early trials.
For more insightful reads, check out the following articles:
– How race became prevalent in medical decision-making tools (STAT)
– Feds abandoned a plan to curb Medicare Advantage overbilling following industry opposition (KFF Health News)
– AI is aiding in unraveling the mystery of the biology of smell (Nature)
Stay tuned for more updates and be sure to subscribe to InnovationRx for the latest healthcare news delivered straight to your inbox.
